Last reviewed · How we verify
Amlodipine/Losartan/Chlorthalidone
This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuresis.
This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuresis. Used for Hypertension (marketed combination therapy).
At a glance
| Generic name | Amlodipine/Losartan/Chlorthalidone |
|---|---|
| Also known as | Amosartan Plus Tab. 5/100/12.5 mg |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diuretic) |
| Target | L-type calcium channels, AT1 angiotensin II receptor, sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine blocks L-type calcium channels in vascular smooth muscle to cause vasodilation. Losartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release. Chlorthalidone is a thiazide-like diuretic that reduces blood volume and sodium reabsorption. Together, these agents provide synergistic blood pressure reduction for patients requiring multi-drug therapy.
Approved indications
- Hypertension (marketed combination therapy)
Common side effects
- Peripheral edema
- Dizziness
- Fatigue
- Hypokalemia
- Hyperuricemia
- Headache
Key clinical trials
- Hypertension in Young Adults Trial (PHASE2)
- Arterial Stiffness and Blood Pressure (NA)
- Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease (PHASE4)
- An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
- The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (NA)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: